Susquehanna International Group, LLP Galecto, Inc. Call Options Transaction History

Susquehanna International Group, LLP

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 11, 2023	BUY	$1.68 - $2.84 $61,992 - $104,796	36,900 New	36,900 $92,000
Q4 2022 Feb 14, 2023	SELL	$1.06 - $58.5 $20,034 - $1.11 Million	-18,900 Reduced 64.73%	10,300 $11,000
Q3 2022 Nov 14, 2022	BUY	$1.59 - $60.0 $46,428 - $1.75 Million	29,200 New	29,200 $55,000

1.52M

100

100

Ticker GLTO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,395,700
Market Cap $180M
Description
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.